IRIS
ZUCALI, PAOLO ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.688
AS - Asia 2.999
EU - Europa 1.417
SA - Sud America 1.220
AF - Africa 248
Continente sconosciuto - Info sul continente non disponibili 20
OC - Oceania 6
AN - Antartide 1
Totale 11.599
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.540
SG - Singapore 1.727
BR - Brasile 1.030
CN - Cina 527
FI - Finlandia 326
VN - Vietnam 324
IE - Irlanda 288
NG - Nigeria 190
IT - Italia 183
DE - Germania 139
FR - Francia 106
CA - Canada 101
SE - Svezia 91
GB - Regno Unito 85
HK - Hong Kong 81
AR - Argentina 77
TR - Turchia 69
NL - Olanda 68
IN - India 43
BD - Bangladesh 42
EC - Ecuador 39
ID - Indonesia 32
IL - Israele 28
MX - Messico 27
IQ - Iraq 23
CO - Colombia 22
ES - Italia 19
RU - Federazione Russa 19
UA - Ucraina 19
ZA - Sudafrica 17
JP - Giappone 16
BE - Belgio 14
CL - Cile 14
MA - Marocco 14
EU - Europa 13
PL - Polonia 13
VE - Venezuela 13
IR - Iran 12
PY - Paraguay 12
PK - Pakistan 11
TW - Taiwan 11
UZ - Uzbekistan 10
EG - Egitto 9
AE - Emirati Arabi Uniti 8
A2 - ???statistics.table.value.countryCode.A2??? 7
DO - Repubblica Dominicana 7
DZ - Algeria 7
PE - Perù 7
CH - Svizzera 6
LT - Lituania 6
AU - Australia 5
CZ - Repubblica Ceca 5
JM - Giamaica 5
NP - Nepal 5
UY - Uruguay 5
AT - Austria 4
GR - Grecia 4
JO - Giordania 4
KE - Kenya 4
TN - Tunisia 4
BA - Bosnia-Erzegovina 3
ET - Etiopia 3
GE - Georgia 3
HN - Honduras 3
OM - Oman 3
PT - Portogallo 3
SA - Arabia Saudita 3
AL - Albania 2
AZ - Azerbaigian 2
BG - Bulgaria 2
BH - Bahrain 2
DK - Danimarca 2
MK - Macedonia 2
MY - Malesia 2
NO - Norvegia 2
RO - Romania 2
AF - Afghanistan, Repubblica islamica di 1
AQ - Antartide 1
BY - Bielorussia 1
EE - Estonia 1
GT - Guatemala 1
GY - Guiana 1
KG - Kirghizistan 1
KR - Corea 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
NI - Nicaragua 1
NR - Nauru 1
PA - Panama 1
PH - Filippine 1
PR - Porto Rico 1
PS - Palestinian Territory 1
QA - Qatar 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
Totale 11.599
Salva come PNG Salva come JPEG
Città #
Wilmington 915
Chandler 558
Singapore 532
The Dalles 422
San Mateo 378
Shanghai 341
Dallas 325
Helsinki 317
Dublin 288
Ann Arbor 262
Ashburn 237
Benin City 190
Lawrence 187
Princeton 187
Leawood 179
New York 161
Ho Chi Minh City 136
Woodbridge 121
Beijing 106
São Paulo 101
Fairfield 100
Paris 100
Boardman 96
Hong Kong 78
Hanoi 66
Amsterdam 65
Milan 61
Toronto 58
Kocaeli 52
Los Angeles 44
London 41
Phoenix 41
Rio de Janeiro 31
Seattle 31
Santa Clara 29
San Diego 25
Curitiba 24
Redwood City 24
Norwalk 21
Belo Horizonte 20
Council Bluffs 19
Porto Alegre 18
Brasília 17
Columbus 17
Naples 15
Brussels 14
Munich 14
Stockholm 14
Monmouth Junction 13
Fortaleza 12
Quito 12
Salvador 12
Warsaw 12
Boston 11
Brooklyn 11
Campinas 11
Carapicuíba 11
Pune 11
Redmond 11
Da Nang 10
Guayaquil 10
Thái Bình 10
Biên Hòa 9
Buenos Aires 9
Dhaka 9
Jakarta 9
Santo André 9
Tashkent 9
Vancouver 9
Asunción 8
Atlanta 8
Chennai 8
Guarulhos 8
Houston 8
Mexico City 8
Montreal 8
Tokyo 8
Andover 7
Bắc Ninh 7
Charlotte 7
Haiphong 7
Joinville 7
San Francisco 7
Santiago 7
Sorocaba 7
Taipei 7
Winnipeg 7
Ankara 6
Ardabil 6
Baghdad 6
Balneário Camboriú 6
Casablanca 6
Caxias do Sul 6
Denver 6
Des Moines 6
Jundiaí 6
Medellín 6
Nanjing 6
Nova Iguaçu 6
Recife 6
Totale 7.510
Salva come PNG Salva come JPEG
Nome #
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer 123
VINORELBINE (V) IN PEMETREXED-PRETREATED PATIENTS (PTS) WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 110
Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study) 110
Gene methylation in pleural mesothelioma : Correlations with clinico-pathological features and patient’s follow-up 109
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 107
721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study 98
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 96
Treatment of malignant pleural mesothelioma: current status and future directions 94
Neutrophil to Lymphocyte Ratio (NLR) as predictive factor in patients with metastatic soft tissue sarcoma (STS) treated with trabectedin (T). 91
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer 86
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 86
Short schedule of cisplatin and vinorelbine: A dose-finding study in non-small-cell lung cancer 86
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 85
PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 84
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial 84
Advances in the biology of malignant pleural mesothelioma 83
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 82
Digital analysis of intratumoural heterogeneity reveals higher leucocytic infiltrate in VETC (Vessels Encapsulating Tumour Clusters) areas 81
A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma 79
Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: Can it be safely associated with fluorouracil-based chemotherapy? 76
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF 76
Computed tomography (CT)-derived radiomic features differentiate prevascular mediastinum masses as thymic neoplasms versus lymphomas 76
Irinotecan and raltitrexed: an active combination in advanced colorectal cancer 75
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors 73
Targeted therapy for thymic epithelial tumors: a new horizon ? Review of the literature and two cases reports 73
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 73
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma 72
Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non-Small Cell Lung Cancer Patients Treated with Gefitinib 71
Prophylaxis of central venous catheter-related thrombosis with minidose warfarin: Analysis of its use in 427 cancer patients 71
Assessment of tumor response in malignant pleural mesothelioma 71
Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma 71
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 71
Anti-angiogenic therapies for malignant pleural mesothelioma 71
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors 70
Reproducibility of the WHO classification of thymomas: practical implications 70
Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study 70
Malignant mesothelioma-associated inflammatory microenvironment promotes tumor progression via GPNMB 69
New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma 68
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey 67
Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen 67
Prognostic and predictive role of [F-18]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy 66
Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [F-18]fluorodeoxyglucose 66
Expression and mutational status of c-kit in thymic epithelial tumors 66
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 66
Activity and safety of trabectedin in patients with sarcomatoid / biphasic malignant pleural mesothelioma (MPM) 65
Baseline Radiomic CT Features Differentiate Mediastinal Masses As Thymic Neoplasms Or Lymphomas 65
Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors 64
Precision medicine in Salivary Gland Carcinoma: Insights from breast and prostate cancer 64
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin 63
Phase II Study of Asparagine-Glycine-Arginine-Human Tumor Necrosis Factor alpha, a Selective Vascular Targeting Agent, in Previously Treated Patients With Malignant Pleural Mesothelioma 63
Survival Outcomes in Malignant Pleural Mesothelioma Patients Fit for Surgery According to Type of Procedure and Completeness of Resection 63
Insulin-Like Growth Factor-1 Receptor and Phosphorylated AKT-Serine 473 Expression in 132 Resected Thymomas and Thymic Carcinomas 63
Management of germ cell tumors during the outbreak of the novel coronavirus disease‐19 pandemic: a survey of international expertise centers 63
"One marker does not fit all": additional translational and validation studies are needed to identify faithful predictors of pemetrexed activity in mesothelioma 62
Biology and management of malignant pleural mesothelioma 61
[Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?] 61
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients 60
Antiproliferative effects of novel aliphatic acetogenin analogs against aggressive solid tumor cell lines 60
Baseline and early change of systemic inflammation index (bSII and ΔSII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study 60
Vessels encapsulating tumour clusters (VETC) in renal cell carcinoma (RCC). prognostic role and predictive value to tyrosine kinase inhibitors (TKI) therapy. A Bayesian retrospective clinico-pathological study 60
Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study 59
Role of SBRT with VMAT technique and FFF beams for lymph-node metastases in oligometastatic patients from genitourinary malignancies 58
A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors 58
SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial 58
Bladder metastases of appendiceal mucinous adenocarcinoma: a case presentation 58
Positron emission tomography with F18-fluorodeoxyglucose (FDG-PET) in malignant pleural mesothelioma (MPM): Prediction of response to chemotheraphy by quantitative assessment of standard uptake value (SUV) 57
IMPACT OF SOLUBLE TUMOR NECROSIS FACTOR-RECEPTORS (STNF-RS) SHEDDING ON OUTCOME IN PATIENTS TREATED WITH NGR-HTNF 57
A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors 57
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma 57
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma 56
Imaging biomarkers in primary brain tumours 56
The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma 56
Advances in drug treatments for mesothelioma 55
Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study 55
Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma 55
Phase II study of Pemetrexed and Carboplatin plus Bevacizumab as first-line therapy in malignant pleural mesothelioma 55
Malignant pleural mesothelioma (MPM) evaluation with C-11-methionine PET/CT before and after talc pleurodesis 55
Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. 55
The neural phenotype in invasive urothelial carcinoma patients: Alternative score detection and prognostic implication 55
SNPs in PI3K-PTEN-mTOR and brain metastases in NSCLC--letter 55
NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study 54
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 54
Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma 54
Safety and activity of Combined AVElumab with Axitinib in unresectable or metastatic Thymomas B3 and Thymic carcinomas: The CAVEATT study 54
Src as a potential therapeutic target in non-small-cell lung cancer 54
Positron emission tomography with F18-fluorodeoxyglucose (FDG-PET) in malignant pleural mesothelioma (MPM): Evaluation of response to chemotherapy by quantitative assessment of standardized uptake value (SUV) 53
Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice. 53
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin 53
Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors 53
THE ROLE OF THYMIDTYLATE SYNTHASE (TS) AND EXCISION REPAIR CROSS-COMPLEMENTING GROUP 1 (ERCC1) IMMUNOHISTOCHEMICAL EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) PATIENTS TREATED WITH PEMETREXED AND CARBOPLATIN 53
A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1 53
Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study 53
Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs 53
The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas 52
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma 52
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer 52
PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS 51
Phase I trial of tivantinib in combination with carboplatin and pemetrexed as first-line treatment in patients with advanced nonsquamous non small cell lung cancer or malignant pleural mesothelioma 51
Future developments in the management of malignant pleural mesothelioma 51
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study 51
Totale 6.717
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.434
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.434
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.846 0 0 0 0 0 659 286 119 358 215 7 202
2021/20221.014 49 29 28 185 15 6 37 128 100 112 290 35
2022/20231.975 408 65 217 169 131 127 6 127 322 224 161 18
2023/20241.345 117 142 244 40 30 183 84 78 27 28 140 232
2024/20252.264 20 70 23 38 68 270 112 187 316 546 292 322
2025/20263.297 917 624 529 921 240 66 0 0 0 0 0 0
Totale 11.866